Literature DB >> 27838461

A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis.

Miriam Wade1, Sara Tai2, Yvonne Awenat3, Gillian Haddock3.   

Abstract

People diagnosed with psychosis, such as those with schizophrenia-related disorders, are routinely prescribed neuroleptic medication as a primary treatment. Despite reported benefits of neuroleptic treatment for symptom remission and relapse prevention, discontinuation rates are high. Research examining factors associated with neuroleptic non-adherence report inconsistent findings. Reasons for adherence to neuroleptic medication are under-researched. The current review aimed to synthesise evidence exploring service-user self-reported reasons for adherence and non-adherence to neuroleptic medication. A systematic literature search of databases and reference list searching identified 21 studies investigating service-user accounts of reasons for adherence and/or non-adherence to neuroleptic medication. Qualitative, quantitative and mixed-method studies were included in the review. Several themes of reasons were identified. Reasons for both adherence and non-adherence were largely similar; medication efficacy, compatibility with personal medication or religious beliefs, side-effects and the influence of relationships with other people. Experiences of stigma and economic difficulties were generally identified as reasons for non-adherence only while experiences of fear and coercion were identified as reasons for adherence only. The review identified crucial factors which may aid service providers in bettering treatment for people with psychosis and will provide evidence which could contribute to future prescribing guidelines.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adherence; Antipsychotic medication; Neuroleptic medication; Non-adherence; Psychosis; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27838461     DOI: 10.1016/j.cpr.2016.10.009

Source DB:  PubMed          Journal:  Clin Psychol Rev        ISSN: 0272-7358


  9 in total

1.  Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial.

Authors:  Deanna L Kelly; Megan M Powell; Heidi J Wehring; MacKenzie A Sayer; Ann Marie Kearns; Ann L Hackman; Robert W Buchanan; Rebecca B Nichols; Heather A Adams; Charles M Richardson; Gopal Vyas; Robert P McMahon; Amber K Earl; Kelli M Sullivan; Fang Liu; Sarah E Luttrell; Faith B Dickerson; Stephanie M Feldman; Supriya Narang; Maju M Koola; Peter F Buckley; Jill A RachBeisel; Joseph P McEvoy
Journal:  J Clin Psychopharmacol       Date:  2018-08       Impact factor: 3.153

2.  Bridging the gap between physical and mental illness in community pharmacy (PharMIbridge): protocol for an Australian cluster randomised controlled trial.

Authors:  Amanda J Wheeler; Claire L O'Reilly; Sarira El-Den; Joshua Byrnes; Robert S Ware; Sara S McMillan
Journal:  BMJ Open       Date:  2020-07-23       Impact factor: 2.692

3.  Barriers to medication adherence for rural patients with mental disorders in eastern China: a qualitative study.

Authors:  Xiaoyun Chai; Ying Liu; Zhuxin Mao; Shunping Li
Journal:  BMC Psychiatry       Date:  2021-03-08       Impact factor: 3.630

4.  Views of Schizophrenia Among Future Healthcare Professionals: Differences in Relation to Diagnostic Labelling, Causal Explanations, and Type of Academic Degree Program.

Authors:  Lucia Sideli; Crocettarachele Sartorio; Laura Ferraro; Giuseppe Mannino; Serena Giunta; Francesca Giannone; Fabio Seminerio; M Valentina Barone; Giuseppe Maniaci; Simonetta Montana; Fulvio Marchese; Daniele La Barbera; Caterina La Cascia
Journal:  Clin Neuropsychiatry       Date:  2021-10

5.  Tapered discontinuation vs. maintenance therapy of antipsychotic medication in patients with first-episode schizophrenia: Obstacles, findings, and lessons learned in the terminated randomized clinical trial TAILOR.

Authors:  Anne Emilie Stürup; Carsten Hjorthøj; Nikolai Albert; Signe Dolmer; Merete Birk; Bjørn H Ebdrup; Lene Falgaard Eplov; Heidi Jensen; Ditte Lammers Vernal; Helene Speyer; Ole Mors; Merete Nordentoft
Journal:  Front Psychiatry       Date:  2022-07-22       Impact factor: 5.435

6.  Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance.

Authors:  Maria S Neumeier; Stephanie Homan; Stefan Vetter; Erich Seifritz; John M Kane; Maximilian Huhn; Stefan Leucht; Philipp Homan
Journal:  Schizophr Bull       Date:  2021-10-21       Impact factor: 7.348

7.  The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index.

Authors:  Daniel Schöttle; Wolfgang Janetzky; Daniel Luedecke; Elmar Beck; Christoph U Correll; Klaus Wiedemann
Journal:  BMC Psychiatry       Date:  2020-02-22       Impact factor: 3.630

8.  Examining healthcare professionals' beliefs and actions regarding the physical health of people with schizophrenia.

Authors:  Alexandra Berry; Richard J Drake; Alison R Yung
Journal:  BMC Health Serv Res       Date:  2020-08-20       Impact factor: 2.655

Review 9.  Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.

Authors:  Edward Chesney; Dominic Oliver; Philip McGuire
Journal:  Psychopharmacology (Berl)       Date:  2021-07-13       Impact factor: 4.415

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.